1	Quantification of impact of COVID-19 pandemic on cancer screening programmes -a case
2	study from Argentina, Bangladesh, Colombia, Morocco, Sri Lanka and Thailand
3	Eric Lucas ¹ , Raul Murillo ² , Silvina Arrossi ³ , Martin Bárcena ⁴ , Youssef Chami ⁵ , Ashrafun
4	Nessa ⁶ , Suraj Perera ⁷ , J Padmaka Silva ⁸ , Suleeporn Sangrajrang ⁹ , Richard Muwonge ¹ ,
5	Partha Basu ^{1*}
6	¹ Early Detection, Prevention and Infections Branch, International Agency for Research on
7	Cancer, Lyon, France
8	² Centro Javerinao de Oncología - Hospital Universitario San Ignacio, Bogotá, Colombia
9	³ Investigadora CEDES/CONICET, Argentina
10	⁴ Instituto Provincial del Cáncer, Jujuy, Argentina
11	⁵ Foundation Lalla Salma Cancer prevention and treatment, Rabat, Morocco
12	⁶ Department of Gynaecological Oncology, Bangabandhu Sheikh Mujib Medical University,
13	Bangladesh
14	⁷ National Cancer Control Programme, Ministry of Health, Sri Lanka
15	⁸ Family Health Bureau, Ministry of Health, Sri Lanka
16	⁹ National Cancer Institute, Department of Medical Services, Ministry of Public Health,
17	Bangkok, Thailand
18	

19 *Corresponding Author

- 20 Partha Basu MD, PhD
- 21 Head, Early Detection, Prevention & Infections Branch
- 22 International Agency for Research on Cancer (WHO)
- 23 25 avenue Tony Garnier, 69007 Lyon, France
- 24 Tel: +33 764485370
- 25 E-mail address: basup@iarc.who.int

26 Abstract

It is guite well-documented that the COVID-19 pandemic disrupted cancer screening services in 27 all countries, irrespective of their resources and healthcare settings. While quantitative estimates 28 on reduction in volume of screening tests or diagnostic evaluation are readily available from the 29 high-income countries, very little data is available from the low- and middle-income countries 30 (LMICs). From the CanScreen5 global cancer screening data repository we identified six LMICs 31 through purposive sampling based on the availability of cancer screening data at least for the 32 33 years 2019 and 2020. These countries represented different human development index (HDI) categories and were from Asia (Bangladesh and Thailand), Africa (Morocco) and Latin America 34 (Argentina and Colombia). The reduction in the volume of tests in 2020 compared to the 35 36 previous years ranged from 14.1% in Bangladesh to 72.9% in Argentina (regional programme) for cervical screening, from 14.1% in Bangladesh to 52.2% in Morocco for breast cancer 37 38 screening and 30.7% in Thailand for colorectal cancer screening. Number of colposcopies was 39 reduced in 2020 compared to previous year by 88.9% in Argentina, 38.2% in Colombia, 27.4% 40 in Bangladesh and 52.3% in Morocco. The reduction in detection rates of CIN 2 or worse lesions 41 ranged from 20.7% in Morocco to 45.4% in Argentina. Reduction of breast cancer detection by 42 19.2% was reported from Morocco. No association of the impact of pandemic could be seen with HDI categories. Quantifying the impact of service disruptions in screening and diagnostic tests 43 will allow the programmes to strategize how to ramp up services to clear the backlogs in 44 45 screening and more crucially in further evaluation of screen-positives. The data can be used to estimate the impact on stage distribution and avoidable mortality from these common cancers. 46

Keywords: COVID-19; cancer screening; breast; cervix; colorectal; impact; low- and middleincome countries

49 Introduction

Breakout of the coronavirus pandemic in 2019 with the emergence of the SARS-Cov-2 virus 50 51 severely impacted the ability of countries to address and respond to the growing burden of cancers. Mitigation measures such as lockdowns, social distancing norms, travel restrictions etc. 52 along with closure of non-emergency health services disrupted cancer care and imposed access 53 delays (WHO, 2020a). The impact of the COVID-19 pandemic on cancer screening, 54 symptomatic diagnosis of cancer, referral pathways and cancer management has been well-55 documented in high-resourced countries (Jones et al, 2020). In the United States of America, a 56 significant drop in the volume of screening for breast cancer (94%), colon cancer (86%) and 57 cervical cancer (94%) was reported between January 2020, and April 2020 (Epic Health 58 59 Research Network, 2020). However, such quantitative estimates are rarely available from outside 60 of North America, Australia, or Europe.

A cross sectional survey was conducted in 2020 by the International Agency for Research on 61 Cancer (IARC), France to assess the impact of COVID-19 pandemic on cancer screening 62 programs in 17 countries (Villain et al., 2021). Though the survey documented country 63 experiences with programme suspensions, changes in health priorities and curtailment of follow 64 up visits, it was too early to generate any quantitative estimate on their impact on screening and 65 downstream processes. In the present manuscript we have reported impact of the COVID-19 66 67 pandemic on existing cancer screening programmes in selected low- and middle-income countries (LMICs) based on comparison of volume of screening and further assessment of 68 screen-positives, before and during the pandemic. Sampling of the countries/programmes was 69 70 purposive, based on their ability to share cancer screening performance data covering the years before and during the pandemic. We included countries belonging to different categories of 71

human development index (HDI) in our purposive sampling of LMICs to document if impact ofthe pandemic was different among them.

74 Methods

The IARC-led project 'Cancer Screening in Five Continents (CanScree5)' is a global repository 75 76 of information on cancer screening programmes, which has collected cancer screening 77 information and data from 84 countries (including LMICs) till date (Basu et al., 2019). LMICs 78 reported to be collecting screening performance data on yearly basis were selected out of the 79 participating countries. Among these, we invited focal points of cancer screening programmes 80 from two very high HDI category LMICs (Argentina and Thailand; HDI between 0.8 and 1.0 in 81 2020), two high HDI category LMICs (Colombia and Sri Lanka; HDI between 0.7 and 0.79 in 82 2020) and two medium HDI category LMICs (Bangladesh and Morocco; HDI between 0.55 and 0.69). The cancer screening programme focal points from these countries also informed us that 83 they had data available at least for the years 2019 (pre-pandemic) and 2020 (during the 84 pandemic). None of the programmes from low HDI countries participating in CanScreen5 85 project had quantitative data that could be shared with us. 86

The focal point(s) from each country shared available data on number screened, and number further assessed disaggregated by months or quarters for the years 2019 and 2020 to allow direct comparison. All the countries except Thailand reported for cervical screening programmes. Data was obtained from breast cancer screening programmes in Bangladesh, Colombia, Morocco and Sri Lanka. Colorectal cancer screening programme data was reported from Thailand only. All the countries except Argentina submitted national data. Colombia submitted national data obtained only from two insurance companies representing 23.8% of the total population. Cancer screening

94 data from Morocco was disaggregated by regions and not by months. The qualitative information
95 on the screening protocol and programme organization was collected from the CanScreeen5
96 website (*Basu et al., 2019*).

For each country we have summarized the protocol and organization of the cancer screening programme, screening performance for the years 2019 and 2020, and evolution of covid-19 burden based on data available at the WHO COVID-19 dashboard (*WHO*, 2020b). Due to the diversity of protocol, screening tests, referral pathway adopted by the countries and the different information systems used, the data across the countries are not directly comparable. Hence, we have presented the outcomes as case studies from the six target countries.

103 The CanScreen5 project was reviewed by IARC Ethic Committee and was approved for104 collection of programme information and aggregate data on an ongoing basis.

105 **Results**

106 *Case study 1: Argentina (very high HDI category) (Jujuy province)*

Argentina is a federal country divided into 24 provinces. Though the National Ministry of Health provides broad regulatory framework and guidelines, the health programmes are administered at provincial level (*Arrossi et al., 2021*). The National Program on Cervical Cancer Prevention (NPCCP) was relaunched in 2008 targeting women between 25 and 65 years of age (*Arrossi et al., 2015*). HPV testing was introduced in Jujuy through the Jujuy Demonstration project, led by the National Program on Cervical Cancer Prevention. HPV-testing is offered to women aged 30 years and older who attend the public health system. Cytology is used as the triage test (*Arrossi*

et al., 2019). The cervical screening coverage in Argentina was reported to exceed 70% of the
eligible *population (ICO/IARC, 2021a; WHO, 2021a)*.

116 Community transmission of SARS-Cov-2 in Argentina was officially declared on 3 March 2020. As of 25 January 2023, total 10.0 million confirmed cases of COVID-19 and 130,394 deaths 117 (0.35% of population) were reported (WHO, 2020c). Health authorities enforced first national 118 lockdown between 20 March and 26 April 2020. However, partial lockdowns for local 119 120 containment of disease were implemented until 30 August 2020. However, by September-October 2020 Jujuy became one of the Argentinean provinces with highest cumulative infection 121 and mortality rates. During this acute phase of disease spread governmental measures focused 122 mainly on preventing the collapse of the health system. By August-September, 93% of Jujuy 123 124 intensive care beds were occupied with COVID-19 cases. Interruptions in provision of primary 125 health care and problems to access drugs were reported (Bernasconi et al., 2021)

In the JuJuy province, total number of women screened with either cytology or HPV test in a year dropped by 72.9% in 2020 from a total of 58,343 women screened in the year 2019 (Table 1). The impact was most severe during the lockdown period and its immediate aftermath with highest reduction of 96.4% being reported in the month of August 2020. With lifting of sanitary restrictions, a gradual improvement of the number of women screened per month was observed only during the year end (Figure 1a). The recovery was slow due to the persistent high burden of COVID cases.

Number of colposcopies performed on the screen-positive women in 2020 was also drastically reduced by 88.9% (Table 1). The overall proportion of screened women undergoing colposcopy in 2019 was 6.4% with the proportion remaining similar across the months. The proportion was

reduced to only 2.6% in 2020, highlighting the large number of screen positive women missing
their further assessment and possible treatment. Due to smaller number of women being screened
and smaller proportion of screen-positive women being assessed with colposcopy in 2020, there
was 45.4% reduction in the number of cervical intraepithelial neoplasia 2 or worse disease (CIN
2+) being detected, and 42.5% excisional treatment being done in the same year compared to
2019.

142 *Case study 2: Colombia (very high HDI category)*

156

143 Colombia introduced cervical and breast cancer screening programmes in the year 2000. The screening protocol was revised in 2018. Though the updated protocol recommended screening of 144 women between 25 to 29 years with cytology every 3 years and 5-yearly HPV test followed by 145 146 cytology triage for women between 30 to 65 years, cytology was still the most commonly available screening test in 2019-20. Eligible participants are invited for cervical screening using 147 the population lists maintained with general practitioners, primary health centers or insurance 148 companies (IARC, 2023a). National participation to the cervical cancer screening programme is 149 around 70% (ICO/IARC, 2021b; WHO, 2021b). 150

Breast cancer screening is performed with clinical breast examination (CBE) for women aged 40 to 49 years, and with mammography for women aged 50 to 69 years. Only those women not screened in a particular round are sent a written invitation.

First case of COVID-19 was detected on 6 March 2020 in Colombia. As of 25 January 2023,
there have been 6.3 million confirmed cases of COVID-19 with 142,385 deaths reported (0.65%)

of population) (WHO, 2020d). Health authorities imposed the initial lockdown from 24 March to

157 1 September 2020 throughout the country. Containment and other restrictions continued in158 several regions even after the lockdown was withdrawn.

Overall, a 46.3% reduction in the number of women screened with cervical cytology was observed in 2020 compared to 546,756 women screened in 2019 (Table 2a). The drop was most significant during the prolonged lockdown period with a slow recovery after that (figure 1b).

The number of colposcopies performed in 2020 was 38.2% less compared to the same in 2019. During the initial lockdown period the drop exceeded 70%. The proportion of the screened women undergoing colposcopy in 2020 (2.9%) was similar to that in 2019 (2.5%) or 2018 (3.1%; data not shown in the table) and remained almost constant across the months. The reduction in the number of colposcopies was essentially because of a smaller number of women being screened during pandemic and not due to too many screen-positive women missing their further assessment.

The number of screening mammography performed in 2020 was 35.2% lower than the 96,940 169 examinations performed in 2019 (Table 2b). Highest reduction was observed immediately after 170 the announcement of lockdown (85.8% in April). The volume of screening per month regained 171 172 the pre-pandemic level almost immediately after withdrawal of lockdown. The total number of breast biopsies performed in 2020 was only 9.2% lower than that observed in 2019, since the 173 programme could rapidly catch up with the missing biopsies during the lockdown. Proportion of 174 biopsies among the total number of women undergoing mammography remained the same in 175 2020 (4.1%) as compared to 2019 (2.9%) and 2018 (2.7%; data not shown in table), signifying 176 that the rate of further assessment of screen-positives was maintained even during the pandemic 177 178 months.

179 *Case study 3: Sri Lanka (high HDI category)*

Sri Lankan ministry of health introduced breast and cervical cancer screening programmes in the 180 years 1996 and 1998 respectively. For both breast and cervical cancer screening, women are 181 invited through population registers to undergo screening at the age of 35 and a repeat screen at 182 the age 45 (10 years later). Breast cancer sceening is carried out using CBE, while Pap-smear test 183 is used for cervical cancer screening. National screening coverage for cervical cancer is around 184 29.3% (IARC, 2023b). Provincial governments are responsible to carry out screening at Well 185 186 Woman Clinics and send data to the national authorities through an electronic data management 187 system (eRHMIS).

First case of COVID-19 was detected in the country on 27 January 2020. Till 25 January 2023, 1.5 million confirmed cases of COVID-19 and 16,826 deaths were reported (0.04% of the population) (*WHO*, 2020e). Health authorities imposed nationwide lockdown for a brief period between 20 March and 24 March 2020. Partial lockdowns continued in high-prevalence zones.

Compared to 160,938 women screened with cytology in 2019, there was an overall 20.5% reduction in 2020 (Table 3a). Maximum reduction of 97% was documented in March 2020. The screening activities recovered quickly but went down again towards the year end as the number of COVID-19 cases surged (Figure 1c). The number of CIN2+ detected in 2020 was 35.6% lower than that in 2019 with some reduction in detection rate in 2020 (0.7% of the screened women) compared to 2019 (0.9%) and 2018 (1.0%; data not shown in table).

The pattern of changes in breast cancer screening volume in 2020 mimicked changes in cervical screening volume in the same year with a short-lasting but significant drop after the national lockdown (Table 3b). The number went down again at the year-end due to surge in number of

201 COVID-19 cases. Information on further assessment of the screen positive women was not202 available.

203 *Case study 4: Thailand (High HDI category)*

The Ministry of Public Health in cooperation with the National Health Security Office 204 205 introduced breast, cervical and colorectal cancer screening programmes in the years 2014, 2005, 206 and 2018 respectively. Breast cancer screening is performed with CBE. Women between 30 to 207 60 years of age undergo pap-smear in urban settings or VIA test in rural settings every 5 years 208 (IARC, 2023c). HPV test was introduced in 2020 to replace cytology progressively. National 209 cervical screening coverage was estimated to be around 67% in 2020 (ICO/IARC, 2021c; Ploysawang et al., 2021; WHO, 2021c). Colorectal cancer screening is based on the faecal 210 211 immunochemical test (FIT) targeting men and women between 50 to 70 years every 2 years.

Thailand was the first country to report a case outside China on 13 January 2020. As of 25 January 2023, 4.7 million confirmed cases of COVID-19 and 33,836 deaths were reported (0.07% of the population) (*WHO*, 2020f). Health authorities enforced lockdown between 22 March and 30 April 2020.

Data was obtained from colorectal cancer screening programme only. Compared to 832,394 individuals screened in 2019 for colorectal cancer there was an overall 30.7% drop in 2020. (Table 4) The programme managed to screen much higher number of individuals during September to December 2020 compared to same months in the year 2019 as more effort was given to scale up screening in the rural areas where the prevalence of COVID was less compared to the urban areas.

222 *Case study 5: Bangladesh (medium HDI category)*

Bangladesh scaled up the opportunistic breast and cervical cancer screening programmes with 223 224 revised protocols and policies in 2016. For breast cancer screening, CBE is performed on women attending various health facilities starting at 30 years of age. Visual inspection after application 225 of acetic acid (VIA) is the cervical screening test offered to women aged between 30 to 60 years 226 227 every 5 years (IARC, 2023d). The screen positive women are referred for colposcopy at 228 designated centers here treatment is performed based on colposcopic suspicion of high-grade lesions. A customized version of DHIS2 (a free and open-source software platform to collect 229 aggregate and individual-level data) is used to collect data at district and national level, which 230 permitted the analysis of COVID-19 (Basu et al, 2021a). However, information on further 231 assessment of the CBE-positive women was lacking as the information system is yet to be 232 extended to the centers where the women are referred for triple assessment. Till December 2022, 233 4.2 million were screened with VIA and 3.8 million women screened with CBE once in a 234 235 lifetime in the programme. Estimated national coverage of the cervical and breast cancer 236 screening programme of the highly populous country still remains remains very low, around 5% 237 only (IARC, 2023e; ICO/IARC, 2021d).

The first known case of COVID-19 was confirmed on 8 March 2020. By 25 January 2023 there have been 2.0 million confirmed cases of COVID-19 with 29,441 deaths reported (0.02% of the population) (*WHO*, 2020g). The Government enforced a national lockdown from 26 March to 30 May 2020.

The cervical screening performance data presented in Table 5a shows a significantly higher number of women being screened in the pre-pandemic months of 2020 due to introduction of a

system of invitation by community health workers (CHWs) at least in selected districts (figure 1d). Enlistment of the eligible women in the DHIS2 software supported this initiative. A significant reduction in the number of women being screened per month was observed during the lockdown and its immediate aftermath. The number of women screened per month quickly recovered and exceeded the previous year due to certain positive steps taken by the programme to continue with the screening activities (e.g., ramping up screening in the rural areas less affected by COVID-19 and enforcing strict mitigation measures at the screening clinics).

Colposcopy data could be collected only from the largest colposcopy referral center situated in the capital city of Dhaka. The number of colposcopies performed in 2020 was 27.4% less compared to that in 2019 with a maximum reduction of 74.8% being observed during the lockdown months. Number of CIN 2+ detected in 2020 showed an overall decrease of 33.3%.

The number of women being screened for breast cancer per month in 2019 and 2020 closely mimicked those for cervical cancer possibly because same women were subjected to both the tests (Table 5b). A 14.2% drop in overall number of women undergoing CBE was reported in 2020 compared to 2019 with the reduction being highest during the lockdown and a few months post-lockdown. Lower CBE-positivity reported in 2020 compared to 2019 could be incidental as no definite pattern (no association with volume of screening, COVID-19 induced restrictions) was observed.

262 *Case study* 6: *Morocco* (*Medium HDI category*)

Ministry of Health of Morocco introduced breast and cervical cancer screening programme in the year 2010, which was gradually scaled up across all provinces. As per the breast cancer screening protocol updated in 2011, asymptomatic women aged from 40 to 69 years attending

the PHCs are offered CBE every 2 years. VIA test is offered to women aged between 30 to 49 years every 3 years at the PHCs for cervical screening. The programme is opportunistic and supported by highly visible mass media campaigns (e.g., celebration of breast cancer awareness month throughout the month of October each year). Screen-positive women are referred to dedicated cancer diagnosis centres for further evaluation (*IARC*, 2023f). National screening coverage estimation for breast cancer is around 56.1% and for cervical cancer around 27.3% in the year 2019 (*IARC*, 2019).

The first case of COVID-19 was detected on 2 March 2020 in Morocco. As of 25 January 2023, there have been 1.2 million confirmed cases of COVID-19 with 16,296 deaths reported (0.02% of the population) (*WHO*, 2020h). Health authorities imposed a nationwide lockdown between 20 March and 15 June 2020. Quarantines, partial lockdowns and other restrictions continued even after that.

Almost all the regions of the country registered a significant drop in the volume of cervical 278 279 screening in 2020 compared to the previous year resulting a new 55.2% reduction in the number of women screened in 2020 (Table 6a). The drop in screening activities was more in the urban 280 provinces (e.g., 68.2% in Rabat, 61.6% in Fès/Meknès, and 58.5% in Grand Casablanca/Settat) 281 compared to the semi-urban ones. The number of colposcopies performed in 2020 was 52.2% 282 less compared to the number of colposcopies in 2019. However, the proportion of screened 283 women undergoing colposcopy remained same in 2020 (2.8%) as compared to 2019 (2.6%) and 284 2018 (2.1%; data not shown on in table). By cascade effect, the number of CIN2+ detected in 285 2020 was reduced by 20.7%. 286

287 The volume of breast cancer screening in 2020 (N=766,702) reduced to almost half of that in 2019 (N=1,515,604) with a higher impact registered in the urban provinces. A significant drop in 288 further assessment was documented in 2020, with a decrease in number of mammography by 289 290 37.9% compared to the previous year (Table 6b). There was a 19.2% reduction in the number of breast cancers detected in 2020 compared to 2019. Breast cancer detection rate remained 291 292 unchanged (1/1000 women screened in 2019 and 1.4/1000 women screened in 2020) indicating that the programme could provide appropriate further assessment services for the screen positive 293 294 women.

295 Discussion

Breast, cervical and colorectal cancer screening programmes achieving high coverage of the 296 297 eligible population, as well as providing timely and high-quality diagnostic follow-up services can save significant number of lives. Despite all the complexities associated with implementation 298 299 of such programmes and their high resource implications, many LMICs have heavily invested in 300 rolling out cancer screening at population levels with varying amount of success. The COVID-19 outbreak forced most health systems to halt or slow down 'non-urgent' services to reassign staff 301 for COVID-19 related work and reduce footfalls to the health facilities. Unfortunately, cancer 302 screening has been included among such 'non-urgent' services in most countries (WHO, 2020i). 303 304 The consequent reduction in cancer screening test volumes would result in substantial rise in avoidable cancer deaths (Maringe et al, 2020). Overwhelming of health systems due to the 305 pandemic and associated detrimental consequences for the wider health and well-being of the 306 population are likely to affect the countries with limited resources even worse than the high-307 308 income countries. However, little effort has been made to quantify the impact of the pandemic on cancer screening activities in the LMICs. This critical knowledge gap is generally ascribed to the 309

absence of a system of collecting performance data on a regular basis to monitor the screeningprogrammes in these countries.

312 Through CanScreen5 project of IARC we could have access to cancer screening performance data from selected LMICs. HDI has been observed to have a positive correlation with infection 313 rate and COVID-19 mortality rate, primarily due to better quality of data available from 314 countries with high HDI (Liu et al, 2020; Mirahmadizadeh et al, 2022). Population aging and 315 316 higher prevalence of co-morbidities are also responsible for the positive correlation. We categorized the LMICs by HDI to investigate any relationship between HDI and impact of the 317 pandemic on screening performance. The high HDI countries having better healthcare systems 318 are expected to have more resilient screening programmes. However, if MoHs interrupted 319 320 preventive health services, then the possibility of continuing the screening is not related to the 321 resilience of screening programs. Programs and health services had to obey national and 322 provincial regulations in order to guarantee COVID services and also keep the health workforce 323 available for the emergency.

In an ongoing and stable cancer screening programme the monthly or yearly volume of screening 324 tests usually remains similar between consecutive years, as has been demonstrated by the 325 comparison of cervical screening data between 2018 and 2019 in the countries included in our 326 327 study (Figure 1). The drop in the number of monthly or yearly screening volumes reported in our study for 2020 provides a reliable estimate of the number of individuals that missed screening 328 due to the pandemic. Irrespective of the HDI category, every country observed the biggest drop 329 in screening during the lockdown. In almost all countries the first lockdown declared in 2020 330 331 was invariably at a short notice and was highly disruptive to routine healthcare. The health systems didn't get enough time and opportunities to reorganize non-emergency services like 332

cancer screening. The screen-eligible individuals were very much hesitant to visit health 333 facilities due the fear of getting infected. As the lockdowns were withdrawn and the health 334 systems adopted several measures to get adjusted to the new situation, the volume of screening in 335 most of the programmes gradually returned back to the pre-pandemic level, as demonstrated in 336 our study. Nonetheless, during the intervening period thousands of individuals have missed their 337 338 screening, which will have a significant impact on cancer mortality in due course. What is more worrying is our observation that many of the screen-positive individuals in some of the countries 339 missed their further assessment and as a result there were fewer detection of precancers and 340 341 cancers among them.

In addition to the impact of screening coverage, the speed of recovery may have different impact by type of cancer. For cervical and colorectal cancers, the aim is to detect precancerous lesions, thus giving more time to catch up unscreened populations without major impact on incidence, whereas screening for breast cancer is aimed at detection of invasive disease and a detrimental effect on screening coverage with slow recovery would have a greater impact on breast cancer mortality.

The reduction in the test volumes in 2020 compared to previous year observed in the LMICs was 348 quite comparable to that observed in high income countries (e.g., cancer screening test volumes 349 were reduced by 40% overall in 2020 in cancer screening programmes in Ontario, Canada) 350 (Walker et al, 2021). Some of the LMIC programmes demonstrated remarkable resilience by 351 catching up with the unscreened eligible individuals, at least partially, within a short period of 352 time. This included both high HDI countries (e.g., breast cancer screening in Colombia, 353 354 colorectal cancer screening in Thailand) and medium HDI countries (e.g., breast and cervical cancer screening in Bangladesh). In addition to creating 'safe' facilities for the screen-eligible 355

individuals, Bangladesh and Thailand expanded the screening activities to the rural and hard-toreach areas where the COVID-19 prevalence was not high due to low population density (*Basu et al*, 2021a). Despite experiencing a significant drop in the volume of screening in 2020, the
breast and cervical screening programmes in Colombia and Morocco managed to ensure further
assessment of the screen positive women essentially by strengthening the referral pathways (e.g.,
having dedicated cancer diagnostic clinics outside the routine health facilities for the screenpositive women to attend).

Cancer screening and further assessment of screen positive individuals were significantly 363 impacted by the pandemic induced service discontinuation, containments and travel restrictions 364 by all programmes irrespective of their settings. Such disruptions may happen in future as well, 365 366 due to not only natural calamities but also political turmoil. Since all countries are trying to 'build back' their health systems better, attention should be given to make them more resilient 367 and equipped to prevent, diagnose and provide care for non-communicable diseases including 368 369 cancer. Unlike COVID-19, cancer is a pandemic that is going to stay and likely to get worse with 370 time. By introducing pragmatic protocols for screening (e.g., less frequent screening with more 371 sensitive tests, self-collection of samples preferably at home), further assessment (e.g., molecular 372 tests to triage self-collected samples) and treatment (e.g., screen and treat for cervical 373 precancers), and use of technologies like telemedicine for consultation or mobile application for 374 delivery of test results the programmes can reduce the necessity for the screen eligible 375 individuals to visit health facilities too frequently (Basu et al, 2021b). Learning lessons from each other is crucial. 376

We have produced the rarely available quantitative data on the change in screening volumes during COVID pandemic in selected LMICs. Modelers may use the data to estimate the

379 additional number of cases that would be detected in advanced stage or excess deaths that are expected, as has been done in several high-income countries (Castanon et al., 2020; Yong et al, 380 2021). Our study has several limitations. Many of the programmes could not provide data across 381 the screening continuum (screening, further assessment, detection of disease and treatment), 382 which precluded a complete assessment of the pandemic impact. This was essentially because 383 most LMIC programmes do not have an effective health information system to collect data 384 across screening pathways for programme monitoring and quality assurance. There may be 385 several reasons that may decrease or increase the volume of screening in a particular year and 386 387 could have impacted our estimates of COVID-19 impact. The number of individuals being screened is usually high with the launch of a new programme or initiation of a new round of 388 screening. This happened with the colorectal cancer screening programme in Thailand in our 389 study as they initiated a new round in 2020. In a regularly screened population, the number of 390 individuals screened may come down during the end of a particular screening round. However, 391 this was not the case in any of the programmes included in our study. 392

To conclude, our analysis demonstrates the profound impact of COVID-19 pandemic on cancer screening services irrespective of HDI category of the countries. It is important for all programmes to strategize how to ramp up services to clear the backlogs in screening and more crucially in further evaluation of screen-positives. Having a robust information system to collect cancer screening data is imperative to monitor screening-related service volumes and backlogs. Well-coordinated, decisive, and collective actions remain critical to make screening programmes more equitable and resilient in the face of natural and geo-political calamities.

400 **Competing interests**: None

401 **Funding:** None.

Author contributions: PB conceptualized the study. EL, RMuw analyzed the data. RMur, SA,
MB, YC, AN, SP, PS and SS provided data collection. PB and EL manuscript drafting, and
revision. All authors read and approved the final manuscript.

405 Data availability: All data generated or analysed during this study are included in the
406 manuscript.

407 Disclaimer: Where authors are identified as personnel of the International Agency for Research
408 on Cancer / World Health Organization, the authors alone are responsible for the views
409 expressed in this article and they do not necessarily represent the decisions, policy or views of
410 the International Agency for Research on Cancer / World Health Organization.

411 References

Arrossi S, Thouyaret L, Laudi R, Marín O, Ramírez J, Paolino M, Herrero R, Campanera A.
2015. Implementation of HPV-testing for cervical cancer screening in programmatic
contexts: The Jujuy demonstration project in Argentina. *Int J Cancer* 137:1709-18. doi:
10.1002/ijc.29530. PMID: 25807897.

416 Arrossi S, Paolino M, Laudi R, Gago J, Campanera A, Marín O, Falcón C, Serra V, Herrero R,

417 Thouyaret L. 2019. Programmatic human papillomavirus testing in cervical cancer

- 418 prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-
- and-after retrospective cohort study. *Lancet Glob Health* **7**:e772-e783. doi:
- 420 <u>10.1016/S2214-109X(19)30048-8</u>. PMID: 31097279.

421	Arrossi S, Paolino M, Laudi R, Thouyaret L. 2021. Changing the paradigm of cervical cancer
422	prevention through introduction of HPV-testing: evaluation of the implementation
423	process of the Jujuy Demonstration Project in Argentina. Ecancermedicalscience
424	15 :1199. doi: <u>10.3332/ecancer.2021.1199</u> . PMID: 33889208
425	Basu P, Lucas E, Carvalho AL, Sauvaget C, Muwonge R, Herrero R, Sankaranarayanan R.
426	2019. Cancer Screening in Five Continents. Lyon, France: International Agency for
427	Research on Cancer. Available online: https://canscreen5.iarc.fr Date accessed
428	25/01/2023
429	Basu P, Lucas E, Zhang L, Muwonge R, Murillo R, Nessa A. 2021a. Leveraging vertical
430	COVID-19 investments to improve monitoring of cancer screening programme - A case
431	study from Bangladesh. Prev Med 151:106624. doi: <u>10.1016/j.ypmed.2021.106624</u> .
432	PMID: 34023359
433	Basu P, Alhomoud S, Taghavi K, Carvalho AL, Lucas E, Baussano I. 2021b. Cancer Screening
434	in the Coronavirus Pandemic Era: Adjusting to a New Situation. JCO Glob Oncol. 7:416-
435	424. doi: 10.1200/GO.21.00033. PMID: 33784177.
436	Bernasconi M, Romero MA, Golovanevsky L 2021. Mapping of local public policies in Jujuy
437	in the context of pandemic. Trabajo y Sociedad 22:203-230.
438	Castanon A, Matejka RM, Pesola F, Sasieni P. 2020. The impact of COVID-19 on disruption to
439	cervical screening in England on excess diagnoses. medRxiv. doi: 10.1038/s41416-021-
440	<u>01275-3</u>
441	Epic Health Research Network. 2020. Preventive cancer screenings during COVID-19
442	pandemic. Published 2020. Available online: <u>https://ehrn.org/wp-</u>

.....

-

.

.

443 content/uploads/Preventive-Cancer-Screenings-during-COVID-19-Pandemic.pdf Date 444 accessed 25/01/2023

.

1 ~

1 ~

445	IARC. 2019. Breast and Cervical Cancer Screening Program of Morocco. International Agency
446	for Research on Cancer (IARC) in collaboration with Ministry of Health, Kingdom of
447	Morocco and the Lalla Salma Foundation for Cancer Prevention and Treatment,
448	Morocco. Breast and Cervical Cancer Screening Program of Morocco: Status of
449	implementation, organization and performance. Available from:
450	https://screening.iarc.fr/doc/MorrocoScreeningReport2019.pdf Date accessed 25/01/2023
451	IARC. 2023a. Cancer Screening in Five Continents – Colombia country profile. Lyon, France:
452	International Agency for Research on Cancer. Available online:
453	https://canscreen5.iarc.fr/?page=countryfactsheetbreast&q=COL Date accessed
454	25/01/2023
455	IARC. 2023b. Cancer Screening in Five Continents – Sri Lanka country profile. Lyon, France:
456	International Agency for Research on Cancer. Available online:
457	https://canscreen5.iarc.fr/?page=countryfactsheetcervix&q=LKA Date accessed
458	25/01/2023

IARC. 2023c. Cancer Screening in Five Continents – Thailand country profile. Lyon, France:
 International Agency for Research on Cancer. Available online:
 https://canscreen5.iarc.fr/?page=countryfactsheet&q=THA Date accessed 25/01/2023

IARC. 2023d Cancer Screening in Five Continents – Bangladesh country profile. Lyon, France:
 International Agency for Research on Cancer. Available online:

464	https://canscreen5.iarc.fr/?page=countryfactsheetbreast&q=BGD	Date	accessed
465	25/01/2023		

- 466 IARC. 2023e Cancer Screening in Five Continents Bangladesh country profile. Lyon, France:
- 467 International Agency for Research on Cancer. Available online:
- 468 <u>https://cdn.who.int/media/docs/default-source/country-profiles/cervical-cancer/cervical-</u>
- 469 <u>cancer-bgd-2021-country-profile-en.pdf?sfvrsn=5749d0ab_35&download=true</u> Date
 470 accessed 25/01/2023
- 471 IARC. 2023f. Cancer Screening in Five Continents Morocco country profile. Lyon, France:
- 472 International Agency for Research on Cancer. Available online:
- 473 <u>https://canscreen5.iarc.fr/?page=countryfactsheetcrc&q=MAR</u> Date accessed 25/01/2023
- ICO/IARC. 2021a. ICO/IARC Information Centre on HPV and Cancer. Argentina Human 474 Sheet 2021. 475 Papillomavirus and Related Cancers, Fact Available online: https://hpvcentre.net/statistics/reports/ARG FS.pdf?t=1661326717239 Date accessed 476
- 477 25/01/2023
- ICO/IARC. 2021b. ICO/IARC Information Centre on HPV and Cancer. Colombia Human 478 Papillomavirus and Related Cancers, Fact Sheet 2021. Available online: 479 https://hpvcentre.net/statistics/reports/COL FS.pdf?t=1661332364051 Date accessed 480 25/01/2023 481
- ICO/IARC. 2021c. ICO/IARC Information Centre on HPV and Cancer. Thailand Human
 Papillomavirus and Related Cancers, Fact Sheet 2021. Available online:
 <u>https://hpvcentre.net/statistics/reports/THA_FS.pdf?t=1661340960544</u> Date accessed
 25/01/2023

486	ICO/IARC. 2021d. ICO/IARC Information Centre on HPV and Cancer. Bangladesh Human
487	Papillomavirus and Related Cancers, Fact Sheet 2021. Available
488	online: <u>https://hpvcentre.net/statistics/reports/BGD_FS.pdf?t=1661333484494</u>
489	Jones D, Neal RD, Duffy SRG, Scott SE, Whitaker KL, Brain K. 2020. Impact of the COVID-
490	19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. Lancet
491	Oncol 21:748-750. doi: 10.1016/S1470-2045(20)30242-4. PMID: 32359404
492	Liu K, He M, Zhuang Z, He D, Li H. 2020. Unexpected positive correlation between human
493	development index and risk of infections and deaths of COVID-19 in Italy. One Health.
494	10:100174. doi: 10.1016/j.onehlt.2020.100174. PMID: 33015305
495	Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, Rachet B, Aggarwal A.
496	2020. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis
497	in England, UK: a national, population-based, modelling study. Lancet Oncol. 21:1023-
498	1034. doi: 10.1016/S1470-2045(20)30388-0. PMID: 32702310
499	Mirahmadizadeh A, Ghelichi-Ghojogh M, Vali M, Jokari K, Ghaem H, Hemmati A, Jafari F,
500	Dehghani SS, Hassani AH, Jafari A, Rezaei F. 2022. Correlation between human
501	development index and its components with COVID-19 indices: a global level ecologic
502	study. BMC Public Health. 22:1549. doi: 10.1186/s12889-022-13698-5. PMID:
503	35971079
504	Ploysawang P, Rojanamatin J, Prapakorn S, Jamsri P, Pangmuang P, Seeda K, Sangrajrang S.
505	2021. National Cervical Cancer Screening in Thailand. Asian Pac J Cancer Prev 22:25-
506	30. doi: 10.31557/APJCP.2021.22.1.25. PMID: 33507675

507	Villain P	Carvalho AI	Lucas F	Mosquera I	7hanσ I	Muwonge R	Selmouni F	Sauvaget C
307	v mam i,	Calvallio AL.	Lucas L,	wiosqueia I.	Liang L,	muwonge R,	Schnouin F,	Sauvaget C.

- 508 Basu P; IARC COVID-19 Impact Study Group. 2021. Cross-sectional survey of the
- 509 impact of the COVID-19 pandemic on cancer screening programs in selected low- and
- 510 middle-income countries: Study from the IARC COVID-19 impact study group. Int J
- 511 *Cancer* **149**:97-107. doi: 10.1002/ijc.33500. PMID: 33533501
- 512 Walker MJ, Meggetto O, Gao J, Espino-Hernández G, Jembere N, Bravo CA, Rey M, Aslam
- 513 U, Sheppard AJ, Lofters AK, Tammemägi MC, Tinmouth J, Kupets R, Chiarelli AM,
- 514 Rabeneck L. 2021. Measuring the impact of the COVID-19 pandemic on organized
- 515 cancer screening and diagnostic follow-up care in Ontario, Canada: A provincial,
- 516 population-based study. *Prev Med.* **151**:106586. doi: 10.1016/j.ypmed.2021.106586.
- 517 PMID: 34217413
- 518 WHO. 2020a. The impact of the COVID-19 pandemic on noncommunicable disease resources
- and services: results of a rapid assessment. World Health Organization. Available online:
- 520 https://apps.who.int/iris/handle/10665/334136 Date accessed 25/01/2023
- WHO. 2020b. WHO COVID-19 Dashboard. Geneva: World Health Organization. Available
 online: <u>https://covid19.who.int</u> Date accessed 25/01/2023
- 523 WHO. 2020c. WHO COVID-19 Dashboard Argentina. Geneva: World Health Organization.
- Available online: <u>https://covid19.who.int/region/amro/country/ar Date accessed</u>
 25/01/2023
- WHO. 2020d. WHO COVID-19 Dashboard Colombia. Geneva: World Health Organization.
 Available online: <u>https://covid19.who.int/region/amro/country/co</u> Date accessed
 25/01/2023

- 529 WHO. 2020e. WHO COVID-19 Dashboard Sri Lanka. Geneva: World Health Organization.
- Available online: <u>https://covid19.who.int/region/searo/country/lk</u> Date accessed
 25/01/2023
- 532 WHO. 2020f. WHO COVID-19 Dashboard Thailand. Geneva: World Health Organization.
- Available online: <u>https://covid19.who.int/region/searo/country/th_Date_accessed</u>
 25/01/2023
- WHO. 2020g. WHO COVID-19 Dashboard Bangladesh. Geneva: World Health
 Organization. Available online: <u>https://covid19.who.int/region/searo/country/bd</u>
- 537 WHO. 2020h. WHO COVID-19 Dashboard Morocco. Geneva: World Health Organization.
- Available online: <u>https://covid19.who.int/region/emro/country/ma</u> Date accessed
 25/01/2023
- 540 WHO. 2020i. COVID-19 significantly impacts health services for noncommunicable diseases.
- 541 World Health Organization. Available online: <u>https://www.who.int/ news-room/ detail/</u>
- 542 <u>01-06-2020-covid-19-significantly-impacts-health-services-for-noncommunicable-</u>
- 543 <u>diseases</u> Date accessed 25/01/2023
- 544 WHO. 2021a. World Health Organization Argentina Cervical Cancer Country Profiles.
- 545 Available online: <u>https://cdn.who.int/media/docs/default-source/country-profiles/cervical-</u>
- 546 cancer/cervical-cancer-arg-2021-country-profile-
- 547 <u>en.pdf?sfvrsn=b95861f5_43&download=true</u> Date accessed 25/01/2023
- 548 WHO. 2021b. World Health Organization Colombia Cervical Cancer Country Profiles.
- 549 Available online: <u>https://cdn.who.int/media/docs/default-source/country-profiles/cervical-</u>

- 550 <u>cancer/cervical-cancer-col-2021-country-profile-</u>
- 551 <u>en.pdf?sfvrsn=de4ba607_38&download=true</u> Date accessed 25/01/2023
- 552 WHO. 2021c. World Health Organization Thailand Cervical Cancer Country Profiles.
- 553 Available online: <u>https://cdn.who.int/media/docs/default-source/country-profiles/cervical-</u>
- 554 <u>cancer/cervical-cancer-tha-2021-country-profile-</u>
- 555 <u>en.pdf?sfvrsn=46b9bf49_38&download=true</u> Date accessed 25/01/2023
- 556 Yong JH, Mainprize JG, Yaffe MJ, Ruan Y, Poirier AE, Coldman A, Nadeau C, Iragorri N,
- 557 Hilsden RJ, Brenner DR. 2021. The impact of episodic screening interruption: COVID-
- 558 19 and population-based cancer screening in Canada. *J Med Screen*. **28**:100-107. doi:
- 559 10.1177/0969141320974711. PMID: 33241760

- 561 Figure 1: Number of women screened for cervical cancer in Argentina (a), Colombia (b), Sri
- 562 Lanka (c) and Bangladesh (d) by months in selected years; the bars show the number of COVID-
- 563 19 cases detected by months in 2020; the green bar shows the lockdown period.



564

565

Year of					[Month of s	creening						Total
screening	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	
				Nu	mber of w	omen scre	ened (wit	h cytology	or HPV te	st)			
2019 - n	4,128	4,140	4,457	5,726	5,969	4,036	4,579	5,200	6,205	5,973	5,319	2,611	58,343
2020 - n	3,102	2,577	1,312	291	840	875	214	189	295	1,351	2,608	2,169	15,823
Change - %*	-24.9	-37.8	-70.6	-94.9	-85.9	-78.3	-95.3	-96.4	-95.2	-77.4	-51.0	-16.9	-72.9
	Number of women undergoing colposcopy												
2019 - n	234	272	322	374	314	240	208	378	433	356	318	305	3,754
2020 - n	62	49	37	37	60	43	13	11	18	20	20	45	415
Change - %*	-73.5	-82.0	-88.5	-90.1	-80.9	-82.1	-93.8	-97.1	-95.8	-94.4	-93.7	-85.2	-88.9
				Nu	mber of w	omen dete	ected with	CIN 2 or v	vorse lesia	ns			
2019 - n	23	34	28	41	27	29	18	42	45	30	51	31	399
2020 - n	35	26	15	19	24	21	8	8	10	15	13	24	218
Change - %*	+52.2	-23.5	-46.4	-53.7	-11.1	-27.6	-55.6	-81.0	-77.8	-50.0	-74.5	-22.6	-45.4
					Numb	er of LLETZ	Z or Coniza	ation perfo	ormed				
2019 - n	9	12	13	30	25	16	16	18	18	18	24	20	219
2020 - n	18	10	8	4	19	14	5	4	8	9	18	9	126
Change - %*	+100.0	-16.7	-38.5	-86.7	-24.0	-12.5	-68.8	-77.8	-55.6	-50.0	-25.0	-55.0	-42.5
* Change is ca	lculated as	(numbers	in 2020 - n	umbers ir	2019) / (r	umbers in	2019) x 1(00. HbA. P	uman nani	lloma viru	s. CIN. cer	vical intra	enithelial

Table 1: Monthly change in number of women undergoing screening, colposcopy and/or treatment, and high-grade CIN detected in the

568 cervical cancer screening programme in Jujuy province, Argentina during 2019 and 2020

* Change is calculated as (numbers in 2020 - numbers in 2019) / (numbers in 2019) x 100; HPV: human papilloma virus; CIN: cervical intraepithelial neoplasia; LLETZ: large loop excision of the transformation zone

571 Table 2a: Monthly change in number of women undergoing cytology screening and colposcopy in the national cervical cancer screening

572 programme in Colombia during 2019 and 2020

Year of					N	lonth of s	creening						Total	
screening	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec		
_					Number	of wome	n screene	d (with cy	/tology)					
2019 - n	n 40,561 52,636 47,734 45,274 47,878 48,200 44,987 46,379 49,125 41,662 45,783 36,537 546													
2020 - n	49,680	47,205	26,564	14,510	6,652	14,911	16,482	15,712	22,567	24,593	27,911	26,878	293,665	
Change - %*	+22.5	-10.3	-44.3	-68.0	-86.1	-69.1	-63.4	-66.1	-54.1	-41.0	-39.0	-26.4	-46.3	
					Number	of wome	n underg	oing colp	oscopy					
2019 - n	1,614	1,450	1,222	1,237	1,249	998	1,120	1,182	1,086	1,114	1,030	495	13,797	
2020 - n	1,235	1,165	897	350	485	579	623	684	631	656	697	528	8,530	
Change - %*	-23.4	-19.7	-26.6	-71.7	-61.2	-42.0	-44.4	-42.1	-41.9	-41.1	-32.3	+6.7	-38.2	
* Change is cald	culated as (numbers	in 2020 - I	numbers	in 2019) /	' (number	s in 2019) x 100						

573

574 Table 2b: Monthly change in number of women undergoing mammography screening and biopsies taken in the national breast cancer

575 screening programme in Colombia during 2019 and 2020

Year of					М	onth of so	creening						Total
screening	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	
_				Nui	nber of w	vomen sci	reened (w	vith mam	mograph	y)			
2019 - n	9,406	9,050	7,955	8,880	8,908	7,966	8,174	8,880	8,647	7,779	6,849	4,446	96,940
2020 - n	7,837	9,818	6,855	1,259	2,269	3,196	3,483	3,739	5,125	6,341	7,189	5,731	62,842
Change - %*	-16.7	8.5	-13.8	-85.8	-74.5	-59.9	-57.4	-57.9	-40.7	-18.5	+5.0	+28.9	-35.2
_				Nur	nber of w	omen fro	m whom	biopsies	were take	en			
2019 - n	184	311	255	203	287	228	213	223	226	253	257	194	2,834
2020 - n	211	302	273	98	136	148	201	207	208	264	270	256	2,574
Change - %*	+14.7	-2.9	-7.1	-51.7	-52.6	-35.1	-5.6	-7.2	-8.0	+4.3	+5.0	+32.0	-9.2
* Change is calc	ulated as (numbers i	n 2020 - n	numbers i	n 2019) /	(numbers	in 2019)	x 100					

576	Table 3a: Monthly change in number of	f women undergoing cytology screening a	and high-grade CIN detected in the national cervical cancer
-----	---------------------------------------	---	---

577 screening programme in Sri Lanka during 2019 and 2020

Year of					M	lonth of s	creening						Total
screening	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	-
					Number	of wome	n screene	d (with cy	rtology)				
2019 - n	15,470	21,135	19,656	7,467	12,352	13,038	11,309	11,055	11,590	11,797	11,044	15,025	160,938
2020 - n	18,293	23,313	8,149	222	1,947	9,650	14,519	12,543	12,153	7,658	6,748	12,812	128,007
Change - %*	+18.2	+10.3	-58.5	-97.0	-84.2	-26.0	28.4	+13.5	+4.9	-35.1	-38.9	-14.7	-20.5
				Numl	ber of wo	men dete	cted with	CIN 2 or	worse les	ions			
2019 - n	28	10	9	2	6	10	11	16	13	13	7	24	149
2020 - n	8	10	6	0	2	11	13	6	9	11	12	8	96
Change - %*	-71.4	0.0	-33.3	-100.0	-66.7	+10.0	18.2	-62.5	-30.8	-15.4	+71.4	-66.7	-35.6
* Change is cal	culated as	(numbers	in 2020 - ı	numbers	in 2019) /	′ (number	s in 2019)) x 100; CI	N: cervica	al intraepi	ithelial ne	oplasia	

Table 3b: Monthly change in number of women undergoing CBE screening in the national cervical cancer screening programme in Sri Lanka
 during 2019 and 2020

Year of Month of screening											Total		
screening	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	-
					Numb	er of wor	nen scree	ned (with	n CBE)				
2019 - n	19,972	27,150	26,329	10,288	16,643	17,778	17,947	15,890	16,884	17,667	16,207	20,253	223,008
2020 - n	22,637	28,509	13,254	356	2,303	12,271	17,982	15,563	15,966	10,057	8,558	16,431	163,887
Change - %*	+13.3	+5.0	-49.7	-96.5	-86.2	-31.0	+0.2	-2.1	-5.4	-43.1	-47.2	-18.9	-26.5
* Change is cal	* Change is calculated as (numbers in 2020 - numbers in 2019) / (numbers in 2019) x 100; CBE: clinical breast examination												

- 584 Table 4: Monthly change in number of women undergoing screening with FIT in the national colorectal cancer screening programme in
- 585 Thailand during 2019 and 2020

Year of	f Month of screening												Total	
screening	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec		
	Number of women screened (with FIT)													
2019 - n	33,860	47,449	65,192	80,255	144,943	185,289	120,682	88,974	15,365	10,108	17,909	22,368	832,394	
2020 - n	27,076	33,731	62,283	23,556	38,778	88,622	93,219	70,560	61,219	24,049	22,549	31,608	577,250	
Change - %*	-20.0	-28.9	-4.5	-70.6	-73.2	-52.2	-22.8	-20.7	+298.4	+137.9	+25.9	+41.3	-30.7	
* Change is cal	* Change is calculated as (numbers in 2020 - numbers in 2019) / (numbers in 2019) x 100; FIT: fecal immunochemical test													

588	Table 5a: Change in number of women undergoing VIA screening and colposcopy, and high-grade CIN detected in the national cervical cancer
589	screening programme in Bangladesh during 2019 and 2020

Year of		Month of screening											
screening	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	-
	Number of women screened (with VIA)												
2019 - n	34,132	31,448	39,775	33,559	21,434	26,694	33,366	27,597	35,636	37,019	36,208	34,663	391,531
2020 - n	52,873 57,759 24,600 1,719					5,078	11,740	30,644	30,250	33,466	47,093	39,088	336,407
Change - %*	+54.9	+83.7	-38.2	-94.9	-90.2	-81.0	-64.8	+11.0	-15.1%	-9.6	+30.1	+12.8	-14.1
	Number of women undergoing Colposcopy (data given for each quarter)**												
2019 - n		42	9			34	42		494				1265
2020 - n		44	0			8	6		393				919
Change - %*		+2	.6		-74.8 -20.4								-27.4
	Number of women detected with CIN 2 or worse lesions (data given for each quarter)**												
2019 - n		10	6			6	2				243		
2020 - n			3	8		68				162			
Change - %*			-3	8.7			-33.3						
* Change is ca	lculated as	(number	s in 2020	- number	s in 2019)) / (numb	ers in 201	9) x 100; *	** Data pro	esented a	re from t	he colpos	сору

clinic of the main hospital in Dhaka, Bangladesh; VIA: visual inspection with acetic acid; CIN: cervical intraepithelial neoplasia

592	Table 5b: Change in number of women undergoing CBE and CBE positivity in the national breast cancer screening programme in Bangladesh
593	during 2019 and 2020

Month of screening												Total	
Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	-	
Number of women screened (with CBE)													
33,358	30,164	37,190	33,657	22,077	26,389	33,354	27,678	36,059	37,227	35,866	34,789	387,808	
51,313	57,271	24,508	1,716	2,046	5,022	11,712	30,540	29,991	33 <i>,</i> 336	46,609	38,717	332,781	
+53.8	+89.9	-34.1	-94.9	-90.7	-81.0	-64.9	+10.3	-16.8	-10.5	+30.0	+11.3	-14.2	
Number and percentage of women who tested positive on CBE													
997	506	465	666	1,048	1,333	1,202	875	856	1,012	879	770	10,609	
(3.0)	(1.7)	(1.3)	(2.0)	(4.7)	(5.1)	(3.6)	(3.2)	(2.4)	(2.7)	(2.5)	(2.2)	(2.7)	
594	778	234	37	63	99	114	158	382	272	950	367	4,048	
(1.2)	(1.4)	(1.0)	(2.2)	(3.1)	(2.0)	(1.0)	(0.5)	(1.3)	(0.8)	(2.0)	(0.9)	(1.2)	
3	Jan 3,358 1,313 +53.8 997 (3.0) 594 (1.2)	Jan Feb 3,358 30,164 1,313 57,271 +53.8 +89.9 997 506 (3.0) (1.7) 594 778 (1.2) (1.4)	Jan Feb Mar 3,358 30,164 37,190 1,313 57,271 24,508 +53.8 +89.9 -34.1 997 506 465 (3.0) (1.7) (1.3) 594 778 234 (1.2) (1.4) (1.0)	Jan Feb Mar Apr 3,358 30,164 37,190 33,657 1,313 57,271 24,508 1,716 +53.8 +89.9 -34.1 -94.9 Mumber 997 506 465 666 (3.0) (1.7) (1.3) (2.0) 594 778 234 37 (1.2) (1.4) (1.0) (2.2)	Jan Feb Mar Apr May Numb 3,358 30,164 37,190 33,657 22,077 1,313 57,271 24,508 1,716 2,046 +53.8 +89.9 -34.1 -94.9 -90.7 Number and percent Number and percent Number and percent 997 506 465 666 1,048 (3.0) (1.7) (1.3) (2.0) (4.7) 594 778 234 37 63 (1.2) (1.4) (1.0) (2.2) (3.1)	Jan Feb Mar Apr May Jun Number of won 3,358 30,164 37,190 33,657 22,077 26,389 1,313 57,271 24,508 1,716 2,046 5,022 +53.8 +89.9 -34.1 -94.9 -90.7 -81.0 Number and percentage of 997 506 465 666 1,048 1,333 (3.0) (1.7) (1.3) (2.0) (4.7) (5.1) 594 778 234 37 63 99 (1.2) (1.4) (1.0) (2.2) (3.1) (2.0)	JanFebMarAprMayJunJulNumber of women scree $3,358$ $30,164$ $37,190$ $33,657$ $22,077$ $26,389$ $33,354$ $1,313$ $57,271$ $24,508$ $1,716$ $2,046$ $5,022$ $11,712$ $+53.8$ $+89.9$ -34.1 -94.9 -90.7 -81.0 -64.9 Number and percentage of women997 506 465 666 $1,048$ $1,333$ $1,202$ (3.0) (1.7) (1.3) (2.0) (4.7) (5.1) (3.6) 594 778 234 37 63 99 114 (1.2) (1.4) (1.0) (2.2) (3.1) (2.0) (1.0)	Jan Feb Mar Apr May Jun Jul Aug Number of women screened (with 3,358 30,164 37,190 33,657 22,077 26,389 33,354 27,678 1,313 57,271 24,508 1,716 2,046 5,022 11,712 30,540 +53.8 +89.9 -34.1 -94.9 -90.7 -81.0 -64.9 +10.3 Number and percentage of women who tester 997 506 465 666 1,048 1,333 1,202 875 (3.0) (1.7) (1.3) (2.0) (4.7) (5.1) (3.6) (3.2) 594 778 234 37 63 99 114 158 (1.2) (1.4) (1.0) (2.2) (3.1) (2.0) (1.0) (0.5)	Jan Feb Mar Apr May Jun Jul Aug Sep Number of women screened (with CBE) 3,358 30,164 37,190 33,657 22,077 26,389 33,354 27,678 36,059 1,313 57,271 24,508 1,716 2,046 5,022 11,712 30,540 29,991 +53.8 +89.9 -34.1 -94.9 -90.7 -81.0 -64.9 +10.3 -16.8 Number and percentage of women who tested positive 997 506 465 666 1,048 1,333 1,202 875 856 (3.0) (1.7) (1.3) (2.0) (4.7) (5.1) (3.6) (3.2) (2.4) 594 778 234 37 63 99 114 158 382 (1.2) (1.4) (1.0) (2.2) (3.1) (2.0) (1.0) (0.5) (1.3)	JanFebMarAprMayJunJulAugSepOctNumber of women screened (with CBE)3,35830,16437,19033,65722,07726,38933,35427,67836,05937,2271,31357,27124,5081,7162,0465,02211,71230,54029,99133,336+53.8+89.9-34.1-94.9-90.7-81.0-64.9+10.3-16.8-10.5Number and percentage of women who tested positive on CBE9975064656661,0481,3331,2028758561,012(3.0)(1.7)(1.3)(2.0)(4.7)(5.1)(3.6)(3.2)(2.4)(2.7)594778234376399114158382272(1.2)(1.4)(1.0)(2.2)(3.1)(2.0)(1.0)(0.5)(1.3)(0.8)	JanFebMarAprMayJunJulAugSepOctNov3,35430,16437,19033,65722,07726,38933,35427,67836,05937,22735,8661,31357,27124,5081,7162,0465,02211,71230,54029,99133,33646,609+53.8+89.9-34.1-94.9-90.7-81.0-64.9+10.3-16.8-10.5+30.0Number and percentage of women who tested positive on CBE9975064656661,0481,3331,2028758561,012879(3.0)(1.7)(1.3)(2.0)(4.7)(5.1)(3.6)(3.2)(2.4)(2.7)(2.5)594778234376399114158382272950(1.2)(1.4)(1.0)(2.2)(3.1)(2.0)(1.0)(0.5)(1.3)(0.8)(2.0)	JanFebMarAprMayJunJunAugSepOctNovDecNumber of women screened (with CBE)3,35830,16437,19033,65722,07726,38933,35427,67836,05937,22735,86634,7891,31357,27124,5081,7162,0465,02211,71230,54029,99133,33646,60938,717+53.8+89.9-34.1-94.9-90.7-81.0-64.9+10.3-16.8-10.5+30.0+11.3Number and percentage of women who tested positive on CBE9975064656661,0481,3331,2028758561,012879770(3.0)(1.7)(1.3)(2.0)(4.7)(5.1)(3.6)(3.2)(2.4)(2.7)(2.5)(2.2)594778234376399114158382272950367(1.2)(1.4)(1.0)(2.2)(3.1)(2.0)(1.0)(0.5)(1.3)(0.8)(2.0)(0.9)	

* Change is calculated as (numbers in 2020 - numbers in 2019) / (numbers in 2019) x 100; CBE: clinical breast examination

Year of		Screening site												
screening	Tanger Tetouan Al Hoceima	Fès Meknès	Rabat Salé Kénitra	Béni Mellal Khénifra	Grand Casablanca Settat	Marrakech Safi	Drâa Tafilalet	Souss Massa	Guelmim Oued Noun	Laayoune Sakia El Hamra	Eddakhla Oued Eddahab	-		
	Number of women screened (with VIA)													
2019 - n	10,965	115,348	45,904	15,777	72,186	46,113	8,457	22,723	2,521	1,180	30	341,204		
2020 - n	4,988	44,301	14,596	17,838	29,952	20,324	4,387	13,350	2,437	824	0	152,997		
Change - %*	-54.5	-61.6	-68.2	13.1	-58.5	-55.9	-48.1	-41.2	-3.3	-30.2	-100.0	-55.2		
	Number of women undergoing colposcopy													
2019 - n	899	2,954	1,520	832	1,479	340	244	726				8,994		
2020 - n	303	1,375	865	913	409	105	80	251				4,301		
Change - %*	-66.3	-53.5	-43.1	9.7	-72.3	-69.1	-67.2	-65.4				-52.2		
	Number of women detected with CIN 2 or worse lesions													
2019 - n	39	43	26	20	35	2	4	15				184		
2020 - n	19	34	18	43	14	0	4	14				146		
Change - %*	-51.3	-20.9	-30.8	115.0	-60.0	-100.0	0.0	-6.7				-20.7		

Table 6a: Site-specific change in number of women undergoing VIA screening and/or colposcopy, and high-grade CIN detected in the national

597 cervical cancer screening programme in Morocco during 2019 and 2020

* Change is calculated as (numbers in 2020 - numbers in 2019) / (numbers in 2019) x 100; VIA: visual inspection with acetic acid; CIN: cervical intraepithelial neoplasia

600 Table 6b: Site-specific change in number of women undergoing CBE screening and/or mammography investigations, and breast cancers

601 detected in the national breast cancer screening programme in Morocco during 2019 and 2020

Year of screening	Screening site												Total
	Tanger Tetouan Al Hoceima	Oriental	Fès Meknès	Rabat Salé Kénitra	Béni Mellal Khénifra	Grand Casablanca Settat	Marrakech Safi	Drâa Tafilalet	Souss Massa	Guelmim Oued Noun	Laayoune Sakia El Hamra	Eddakhla Oued Eddahab	
	Number of women screened (with CBE)												
2019 - n	113,755	99,230	269,517	210,892	158,305	249,501	190,757	45,150	150,947	18,569	8,826	155	1,515,604
2020 - n	60,170	76 <i>,</i> 848	99,917	81,357	101,285	117,061	99,441	23,521	85,295	13,648	8,047	112	766,702
Change - %*	-47.1	-22.6	-62.9	-61.4	-36.0	-53.1	-47.9	-47.9	-43.5	-26.5	-8.8	-27.7	-49.4
	Number and percentage of women who tested positive on CBE												
2019 - n	3,908	805	4,956	2,888	2,102	2,572	1,543	632	2,324				21,730
(%)	(3.4)	(0.8)	(1.8)	(1.4)	(1.3)	(1.0)	(0.8)	(1.4)	(1.5)				(1.4)
2020 - n	2,807	418	3,265	1,563	1,674	1,354	976	316	1,244				13,617
(%)	(4.7)	(0.5)	(3.3)	(1.9)	(1.7)	(1.2)	(1.0)	(1.3)	(1.5)				(1.8)
				Numb	er undergoi	ng mammogra	aphy investigo	itions amo	ng CBE posi	itive women	1		
2019 - n	1,772	403	3,506	2,037	1,378	2,489	845	470	1,311				14,211
2020 - n	1,381	269	2,267	982	709	1,334	652	294	936				8,824
Change - %*	-22.1	-33.3	-35.3	-51.8	-48.5	-46.4	-22.8	-37.4	-28.6				-37.9
					N	umber of wom	en detected w	vith breast	cancers				
2019 - n	249	82	346	186	65	204	79	49	115				1,375
2020 - n	213	16	271	174	65	125	91	30	127				1,112
Change - %*	-14.5	-80.5	-21.7	-6.5	0.0	-38.7	15.2	-38.8	10.4				-19.1
* Change is ca	lculated as (numbers in	2020 - num	bers in 201	19) / (numb	ers in 2019) x 1	.00; CBE: clinio	cal breast e	kamination				